Related Experiment Video
Updated: Jun 20, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[PAD regimen for relapsed or refractory patients with multiple myeloma]
Yong-Qing Zhang1, Rong Liang, Qing-Xian Bai
1Department of Hematology, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|September 8, 2009
Summary
The bortezomib, doxorubicin, and dexamethasone (PAD) regimen shows high efficacy in treating relapsed or refractory multiple myeloma (MM). This treatment is particularly effective for MM with extramedullary plasmacytoma and has manageable side effects.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Context:
- Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Relapsed or refractory MM presents significant treatment challenges, necessitating novel therapeutic strategies.
- The PAD regimen combines proteasome inhibitor bortezomib with cytotoxic agents doxorubicin and dexamethasone.
Purpose:
- To evaluate the efficacy and safety of the PAD regimen in patients with relapsed or refractory multiple myeloma.
- To assess treatment response rates, duration of response, and impact on extramedullary disease.
- To characterize the safety profile and tolerability of the PAD regimen.
Summary:
- The study included 17 patients with relapsed/refractory MM who received 2-4 cycles of PAD.
- An overall response rate of 82.4% was observed, including complete responses (23.5%) and very good partial responses (23.5%).
- Median time to progression was 9.5 months, with significant activity against extramedullary plasmacytoma.
Impact:
- The PAD regimen is an effective treatment option for relapsed or refractory MM, including cases with extramedullary involvement.
- Treatment efficacy was independent of traditional prognostic factors.
- Adverse events were generally manageable with supportive care, indicating a favorable safety profile.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...